BELLEVUE, Wash.--(BUSINESS WIRE)--HIMSS17 -- Translational Software®, Inc. (TSI), a leader in the intelligent use of genetic data for clinical decision support, will co-present a session on precision medicine with Inova Translational Medicine Institute at the HIMSS17 Conference & Exhibition taking place Feb. 19-23 at the Orange County Convention Center in Orlando.
Dr. John Deeken, COO of Inova Translational Medicine Institute, and Don Rule, CEO at TSI, will present “Building an Integrated Precision Medicine Infrastructure." The session, scheduled for Monday, Feb. 20, 2017 at 3:00-4:00 PM EST in Room 331A, will offer lessons learned for providers looking to implement genomics-based care and provide tips for how to integrate genomic data into clinical workflows to help clinicians make informed treatment decisions.
“Integrating precision medicine into patient care is one of Inova Health System’s primary goals,” stated Deeken. “Through the implementation of pharmacogenomics (PGx) testing, we learned that providing user-friendly and actionable data at the point of care is critical so physicians can understand the implications of the information quickly. We’ve been working with Translational Software to translate PGx data into highly interpretable information, and look forward to sharing our approach at HIMSS.”
TSI’s proprietary knowledge platform and Application Programming Interface (API) is helping healthcare providers, labs, and information technology vendors to integrate genomic decision support and critical alerts regarding drug efficacy, toxicity and known interactions to guide decision making, minimize adverse reactions and enable physicians to prescribe the most effective medications in real-time.
“One of the biggest benefits of using PGx data that will be discussed in our presentation is how it helps clinicians move from reactive to predictive medicine,” stated Rule. “Having patient-specific clinical intelligence at the point of care results in more effective treatment decisions, better patient outcomes and decreased costs.”
Representatives from TSI will be available at booth #1094 throughout the conference to meet with attendees and discuss how the company is helping healthcare organizations leverage genomic information for precision medicine.
About Translational Software, Inc.
Translational Software provides end-to-end solutions to support laboratories and healthcare providers adopting personalized medicine. Its powerful PGx portal transforms genomic and molecular data into actionable knowledge, integrating the best available clinical decision support with laboratory and clinical information systems to guide therapeutic options for medication management to enhance patient care. For more information visit www.translationalsoftware.com or follow us on LinkedIn.
About Inova Translational Medicine Institute
The Inova Translational Medicine Institute (ITMI) is a not-for-profit research institute delving into the genomics component of personalized medicine. ITMI utilizes genomic and clinical information from patients to develop innovative methods for personalized patient care. Pilot studies at the Institute have generated a large genomic and clinical data set that can be used as pilot data in a variety of fields, from computational biology to psychology as well as more obvious biomedical research applications. ITMI’s goal is to utilize information from its pilot studies to better understand and predict the onset of disease, leading to the implementation of preventive medicine based on the unique genomics of the individual patient.